Results 241 to 250 of about 104,861 (298)

PARP Inhibitors in Genitourinary Cancer: A New Paradigm Beyond Prostate Cancer. [PDF]

Int J Urol
Okuda Y, Kato T, Ishizuya Y, Hayashi T, Yamamoto Y, Hatano K, Kawashima A, Murai J, Nonomura N.   +8 more
europepmc   +1 more source

Germline genetic testing among patients with pancreatic adenocarcinoma: A Pancreatic Cancer Action Network patient survey

Cancer, Volume 132, Issue 10, 15 May 2026.
Abstract Background Approximately 10%–15% of patients with pancreatic ductal adenocarcinoma (PDAC) harbor pathogenic germline genetic alterations with direct therapeutic and hereditary cancer implications, leading to guideline recommendations for universal germline genetic testing regardless of family history.
Udhayvir S. Grewal, Rishi R. Patel, Bradley T. Loeffler, Sydney Rathjens, Kawther Abdilleh, Fatima Zelada‐Arenas, Nicholas J. Hornstein, Timothy J. Brown, Seth J. Concors, Naomi H. Fei, Saima Sharif, Chandrikha Chandrasekharan   +11 more
wiley   +1 more source

Controversies and clinical unknowns in the use of PARP inhibitors in ovarian cancer. [PDF]

Ther Adv Med Oncol
Mukherjee UA, Miller RE, Ledermann JA.
europepmc   +1 more source

Influence of Residual Disease on the Efficacy of PARP Inhibitors in Advanced Epithelial Ovarian Cancer: A Systematic Review and Meta Analysis. [PDF]

Cancers (Basel)
Hwang S, Kim JH, Kim U, Ha HI, Park SY, Lim MC.   +5 more
europepmc   +1 more source

Receipt of PARP Inhibitors in Patients With Metastatic Prostate Cancer Harboring BRCA1/2 Alterations.

JAMA Netw Open
Ostrowski M, Jo Y, Hage Chehade C, Ozay ZI, Gebrael G, Sayegh N, Lin E, Srivastava A, Gordhamer A, Ji R, Li H, Mathew Thomas V, Gupta S, Riaz IB, Maughan BL, Roy S, Agarwal N, Swami U.   +17 more
europepmc   +1 more source

Novel Isoindolinone-Containing PARP Inhibitors: Synthesis and Therapeutic Applications in CNS Cancer Treatment. [PDF]

ACS Med Chem Lett
Zhou X, Liang SH.
europepmc   +1 more source

Hematological toxicity of parp inhibitors in solid tumors: a systematic review and safety meta-analysis. [PDF]

Cancer Metastasis Rev
Maiorano BA, Catalano M, Maiorano MFP, Signori A, Loizzi V, Cormio G, Reni M, Roviello G, Necchi A.   +8 more
europepmc   +1 more source

An Inducible BRCA1 Expression System with In Vivo Applicability Uncovers Activity of the Combination of ATR and PARP Inhibitors to Overcome Therapy Resistance. [PDF]

Cancers (Basel)
Irving E, Morcavallo A, Vohhodina-Tretjakova J, Wijnhoven PWG, Beckett AL, Jacques MP, Evans RS, Moss JI, Staniszewska AD, Forment JV.   +9 more
europepmc   +1 more source

Global Proteomic Determination of the Poly-Pharmacological Effects of PARP Inhibitors Following Treatment of High-Grade Serous Ovarian Cancer Cells. [PDF]

Int J Mol Sci
Perez JM, Barrera-Estrada V, Twigg CAI, Thomas SN.   +3 more
europepmc   +1 more source